|
1
|
Jiao XY, Ren JL, Chen HY, et al: Ala499Val
(C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene:
their correlation with the risk of primary gallbladder
adenocarcinoma: a case-control study in China. Carcinogenesis.
32:496–501. 2011.
|
|
2
|
Jiao XY, Huang JF, Wu SL, et al: HOGG1
Ser326Cys polymorphism and susceptibility to gallbladder cancer in
a Chinese population. Int J Cancer. 121:501–505. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reid KM, Ramos-De la Medina A and Donohue
JH: Diagnosis and surgical management of gallbladder cancer: a
review. J Gastrointest Surg. 11:671–681. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Munn DH and Mellor AL: Indoleamine
2,3-dioxygenase and tumor-induced tolerance. J Clin Invest.
117:1147–1154. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takikawa O: Biochemical and medical
aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan
metabolism. Biochem Biophys Res Commun. 338:12–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soliman H, Mediavilla-Varela M and Antonia
S: Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer
J. 16:354–359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karanikas V, Zamanakou M, Kerenidi T, et
al: Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer.
Cancer Biol Ther. 6:1258–1262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pine R: Convergence of TNFalpha and
IFNgamma signalling pathways through synergistic induction of
IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter
element. Nucleic Acids Res. 25:4346–4354. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshida N, Ino K, Ishida Y, et al:
Overexpression of indoleamine 2,3-dioxygenase in human endometrial
carcinoma cells induces rapid tumor growth in a mouse xenograft
model. Clin Cancer Res. 14:7251–7259. 2008. View Article : Google Scholar
|
|
10
|
Liu P, Xie BL, Cai SH, et al: Expression
of indoleamine 2,3-di-oxygenase in nasopharyngeal carcinoma impairs
the cytolytic function of peripheral blood lymphocytes. BMC Cancer.
9:4162009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyazaki T, Moritake K, Yamada K, et al:
Indoleamine 2,3-dioxygenase as a new target for malignant glioma
therapy. Laboratory investigation. J Neurosurg. 111:230–237. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muller AJ, DuHadaway JB, Donover PS,
Sutanto-Ward E and Prendergast GC: Inhibition of indoleamine
2,3-dioxygenase, an immunoregulatory target of the cancer
suppression gene Bin1, potentiates cancer chemotherapy. Nat Med.
11:312–319. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng J, Cai S, Yi Y, et al: Prevention of
spontaneous tumor development in a ret transgenic mouse model by
ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor
1-methyl tryptophan. Cancer Res. 69:3963–3970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang KS, Li GC, He YW, et al: Curcumin
inhibiting the expression of indoleamine 2,3-dioxygenase induced by
IFN-γ in cancer cells. Zhong Yao Cai. 31:1207–1211. 2008.(In
Chinese).
|
|
15
|
Platanias LC: Mechanisms of type-I- and
type-II-interferon-mediated signalling. Nat Rev. 5:375–386.
2005.PubMed/NCBI
|
|
16
|
Klampfer L, Huang J, Sasazuki T, Shirasawa
S and Augenlicht L: Inhibition of interferon gamma signaling by the
short chain fatty acid butyrate. Mol Cancer Res. 1:855–862.
2003.PubMed/NCBI
|
|
17
|
Chon SY, Hassanain HH, Pine R and Gupta
SL: Involvement of two regulatory elements in
interferon-gamma-regulated expression of human indoleamine
2,3-dioxygenase gene. J Interferon Cytokine Res. 15:517–526. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamaguchi H, Chen CT, Chou CK, et al:
Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced
apoptosis through Egr-1-mediated Bim upregulation. Oncogene.
29:5619–5629. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun PC, Tzao C, Chen BH, Liu CW, Yu CP and
Jin JS: Suberoylanilide hydroxamic acid induces apoptosis and
sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci.
17:762010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vigushin DM and Coombes RC: Histone
deacetylase inhibitors in cancer treatment. Anticancer Drugs.
13:1–13. 2002. View Article : Google Scholar
|
|
22
|
Frew AJ, Johnstone RW and Bolden JE:
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Cancer Lett. 280:125–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zong H, Yin B, Chen J, Ma B, Cai D and He
X: Over-expression of c-FLIP confers the resistance to
TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med.
217:203–208. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qing Y and Stark GR: Alternative
activation of STAT1 and STAT3 in response to interferon-gamma. J
Biol Chem. 279:41679–41685. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi N, Kubota K, Kato S, et al:
FOXP3+ regulatory T cells and tumoral indoleamine
2,3-dioxygenase expression predicts the carcinogenesis of
intraductal papillary mucinous neoplasms of the pancreas.
Pancreatology. 10:631–640. 2010.
|
|
26
|
Munn DH: Indoleamine 2,3-dioxygenase,
tumor induced tolerance and counter regulation. Curr Opin Immunol.
18:220–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Urakawa H, Nishida Y, Nakashima H,
Shimoyama Y, Nakamura S and Ishiguro N: Prognostic value of
indoleamine 2,3-dioxygenase expression in high grade osteosarcoma.
Clin Exp Metastasis. 26:1005–1012. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dai W and Gupta SL: Regulation of
indoleamine 2,3-dioxygenase gene expression in human fibroblasts by
interferon-gamma. Upstream control region discriminates between
interferon-gamma and interferon-alpha. J Biol Chem.
265:19871–19877. 1990.
|
|
29
|
Kadoya A, Tone S, Maeda H, Minatogawa Y
and Kido R: Gene structure of human indoleamine 2,3-dioxygenase.
Biochem Biophys Res Commun. 189:530–536. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konan KV and Taylor MW: Importance of the
two interferon-stimulated response element (ISRE) sequences in the
regulation of the human indoleamine 2,3-dioxygenase gene. J Biol
Chem. 271:19140–19145. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boehm U, Klamp T, Groot M and Howard JC:
Cellular responses to interferon-gamma. Annu Rev Immunol.
15:749–795. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jeong YI, Kim SW, Jung ID, et al: Curcumin
suppresses the induction of indoleamine 2,3-dioxygenase by blocking
the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling
pathway in interferon-gamma-stimulated murine dendritic cells. J
Biol Chem. 284:3700–3708. 2009. View Article : Google Scholar
|
